Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline
Authors:
- 30 April 2024
- journal article
- review article
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 44 (02) , 150-154
Abstract
In the recently updated German S2k Guideline “Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism,” a new chapter was incorporated about recurrent venous thromboembolism (VTE) in patients on anticoagulation treatment. Despite the high efficacy of anticoagulation in most patients, approximately 2% experience a recurrent VTE event while receiving anticoagulant drugs. The proper diagnosis of the recurrent VTE is important and possible only with the knowledge of localization and thrombus burden of the primary VTE event. Possible reasons for recurrent VTE events in patients on anticoagulation are non-adherence to medication, sub-therapeutic drug levels due to resorption disorders or drug interactions, or concomitant disease with high thrombogenicity. Cancer is the most common underlying disease, but it is important to investigate and understand possible other causes whenever a breakthrough VTE event occurs. This results in the recommendation that in patients with VTE recurrence on therapeutic anticoagulation, in particular, the presence of malignant disease, antiphospholipid syndrome, and rare diseases like paroxysmal nocturnal hemoglobinuria or Behçet's disease should be considered. For VTE recurrence during heparin therapy, heparin-induced thrombocytopenia type II needs to be ruled out, even if platelet counts are within the normal range. Although the mechanisms of recurrence on anticoagulation can be evaluated in a certain degree, clinical evidence for the management of recurrent VTE in anticoagulated patients is minimal and mainly based on expert opinion. Switching anticoagulant medication and intensifying anticoagulant treatment are possible options.Keywords
This publication has 23 references indexed in Scilit:
- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial FibrillationEP Europace, 2021
- 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral AnticoagulantsThrombosis and Haemostasis, 2021
- Select Drug-Drug Interactions With Direct Oral AnticoagulantsJACC, 2020
- Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patientsThrombosis Research, 2020
- Treatment of the antiphospholipid syndrome with direct oral anticoagulantsVasa, 2019
- Incidence of Cancer after a Second Unprovoked Venous Thromboembolic EventThrombosis and Haemostasis, 2019
- Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysisThrombosis Research, 2019
- Controversies in the management of cancer-associated thrombosisExpert Review of Hematology, 2016
- Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trialThe Lancet Haematology, 2016
- Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive PatientsCurrent Rheumatology Reports, 2010